Peptide News Digest

Samsung Clears PolyPeptide Tender Threshold, Tirzepatide and Endometrial Cancer, Mosquito Peptides Against Malaria

Samsung wins 87.9% of PolyPeptide in its tender, tirzepatide tracks with less endometrial cancer, and mosquito peptides hit malaria parasites in the lab.

5 stories · Covering industry, research

Editor's Note

Tuesday's biggest peptide story was about factories rather than drugs: Samsung Biologics passed the acceptance threshold in its CHF 1.46 billion offer for PolyPeptide, the Swiss contract maker that produces peptide ingredients for GLP-1 and other drugmakers, pending regulatory approvals. A large Taiwanese team's records study linked tirzepatide to about 28% fewer new endometrial cancer diagnoses over two years, but the comparison group was lifestyle programs, follow-up was short, and the authors said the data do not show prevention. Three lab papers stayed far from the clinic: a Copenhagen study found blood amylin levels useless as a migraine marker, a Johns Hopkins team found four new antimicrobial peptides in the malaria mosquito, two of which damaged parasites, and a Tübingen group found that a scorpion-toxin peptide selective for one potassium channel had little effect in real neurons.

Industry

Samsung Biologics Passes the 66.7% Threshold in Its CHF 1.46 Billion Tender for Peptide Maker PolyPeptide, With 87.9% of Shares Tendered

Samsung Peptide AG, a subsidiary of Samsung Biologics, published a provisional interim result on October 13, 2026 after its main offer period for PolyPeptide Group ended on October 12: 29,014,418 shares, or 87.88% of the shares covered by the CHF 44.31-per-share offer, were tendered, well above the 66.7% minimum, including all 18,375,000 shares held by the largest shareholder, Draupnir Holding, according to the Asia Business Daily. The audited interim result is due October 16, an additional acceptance period runs October 19 to 30, and closing awaits regulatory approvals in Europe, India, Australia, and Brazil, with completion targeted for the end of November.

#polypeptide #samsung-biologics #cdmo #peptide-manufacturing
Research

Tirzepatide Linked to 28% Lower Short-Term Risk of Endometrial Cancer Diagnoses in a TriNetX Study of 354,000 Women

Researchers at Chi Mei Medical Center in Taiwan reported in Diabetology & Metabolic Syndrome on October 13, 2026 a records study in the TriNetX U.S. network that matched 176,981 women with overweight or obesity who started tirzepatide between 2022 and 2025 with the same number in lifestyle programs. Over up to two years, tirzepatide users had a lower rate of new endometrial cancer diagnoses (hazard ratio 0.717), a pattern seen across most subgroups. The authors said the observational, short-term findings do not establish that tirzepatide prevents the cancer.

#tirzepatide #endometrial-cancer #cancer #real-world-evidence
Research

Copenhagen REFORM Study Finds Blood Amylin Levels Do Not Distinguish Migraine or Predict Response to Erenumab

Researchers at the Danish Headache Center reported in Headache on October 13, 2026 that plasma amylin, a hormone closely related to the migraine signal CGRP, did not differ between 121 adults with migraine and 63 healthy controls (about 9 ng/mL in each group), across migraine subtypes, or between people who did and did not respond to 24 weeks of the CGRP-blocking antibody erenumab (Aimovig); levels also did not change during treatment. The authors concluded that blood amylin is not a useful migraine biomarker, though amylin drugs such as pramlintide can still trigger attacks.

#amylin #migraine #cgrp #erenumab
Research

Johns Hopkins Finds 36 New Antimicrobial Peptide Candidates in the Malaria Mosquito, Two of Which Cut Parasite Viability by About 75% to 81%

A Johns Hopkins Bloomberg School of Public Health team reported in npj Antimicrobials and Resistance on October 13, 2026 a genome survey of Anopheles gambiae, the main African malaria mosquito, that identified 36 previously uncharacterized antimicrobial peptide candidates. Lab-made versions of four, named Anolarvin, Konopsin, Sialicin, and Cryptophelin, killed or stopped a broad range of microbes, and the two found mainly in salivary glands, Sialicin and Cryptophelin, reduced the viability of Plasmodium falciparum sporozoites, the parasite stage mosquitoes inject, by about 81% and 75% in lab tests. The authors see them as leads for blocking malaria transmission.

#antimicrobial-peptides #malaria #infectious-disease #preclinical
Research

Tübingen Researchers Find a Scorpion-Toxin Peptide That Blocks One Potassium Channel Has Little Effect on Real Neurons

Neurologists at the University of Tübingen's Hertie Institute reported in Frontiers in Pharmacology on October 13, 2026 that BMK86-P1, a synthetic scorpion-toxin peptide, selectively blocked Kv1.2 potassium channels made only of Kv1.2 units in cells but barely affected channels mixed with Kv1.1, the form common in the brain. In mouse neurons it produced little change in firing or synaptic activity. The authors, who study gene variants in these channels that cause epilepsy, said the work shows the limits of using such toxins as precise research tools.

#venom-peptides #scorpion-toxin #ion-channels #epilepsy

Related Guides